Deciding which of the available genomic tests to use

Multigene assays may provide clinically complementary information to classic clinicopathological tumour features, such as tumour size and grade, in breast cancer. At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Giampaolo Bianchini, MD, of the San Raffaele Scientific Institute, Milan, Italy, reviews the predictive and prognostic value of currently available multigene assays for the management of patients with early stage breast cancer.

This content is supported by Genomic Health, Inc.

Year of Production:
Running Time:
Color/Sound:

2015
02:34
Color/Sound

Comments are closed.